06
08
2022
06/08/2022
Globally Recognized Technology Leader Virginia Gambale Joins Avellino’s Board of Directors
Gambale’s extensive experience will support Avellino’s bioinformatics precision medicine mission.
read more04
20
2022
04/20/2022
Globally Recognized Scientific Policy and Genomics Expert Genya Dana, Ph.D. Joins Avellino as Global Head of Health Policy
Dana’s abundance of policy experience in genomics and biotechnology will help lead Avellino’s next chapter of growth as the company continues to develop its powerful data-centric diagnostic and therapeutic solutions in healthcare.
read more03
24
2022
03/24/2022
City of Hayward, Avellino Lab Mark Two-Year Anniversary of Leadership in Covid-19 Testing
Avellino, one of California’s largest Covid-19 test providers, and the Hayward Fire Department celebrated the two-year anniversary of their joint effort opening the first free, community hosted Covid-19 drive-through testing site, which opened on March 23, 2020 in Hayward, Calif. The commemoration included a Certificate of Commendation, a celebratory lunch, and a donation to the Hayward Firefighters Charitable fund.
read more02
07
2022
02/07/2022
Avellino Adds Respiratory Syncytial Virus (RSV) Assay to its AvellinoCoV2 – Respiratory Test
Avellino has launched an expanded AvellinoCoV2 – Respiratory Test that now detects respiratory syncytial virus (RSV). The test supports an unprecedented RSV, cold and flu season complicated by the continued impact of COVID-19 and the ‘flurona’ infection.
read more02
02
2022
02/02/2022
Omicron Surge Prompts Opening of New Drive-Through Community Covid Testing Site by Leading Bay Area Covid Test Provider
Avellino, one of California’s largest COVID test providers, has opened a new drive-through COVID-19 testing site at its company headquarters in Menlo Park, CA to support the urgent need for greater testing access due to shortages of home tests and long testing lines elsewhere.
read more01
18
2022
01/18/2022
Avellino Enters into Distribution Agreement With Keeler to Sell AvaGen, The Genetic Eye Test
Menlo Park, CA
Avellino and Keeler, a global ophthalmic device manufacturer and distributor, have entered into an agreement where Keeler will distribute AvaGen on its US website. AvaGen is the first genetic test that helps determine a patient’s risk of keratoconus and the presence of TGFBI corneal dystrophies.
read more01
05
2022
01/05/2022
Nationally Recognized Ophthalmologist Dr. Elizabeth Yeu Joins Avellino’s Board of Directors
Menlo Park, CA
Dr. Yeu’s depth of experience will help Avellino as the company continues to provide genetic-based diagnostics for the ophthalmic industry and expands its innovative product pipeline to new disease areas such as glaucoma.
read more11
16
2021
11/16/2021
Avellino Appoints Jon Robson as CEO and Member of the Board of Directors
Menlo Park, California
Avellino Lab USA, Inc. (Avellino) is pleased to announce Jon Robson as the company’s new CEO and member of the Board of Directors. Jon will lead the company’s next phase of innovation and growth, including further integrating Avellino’s depth of genetic expertise with machine learning, AI, and big data. This impactful combination will help the company continue to develop life-changing diagnostics and therapeutics that help improve patient outcomes, along with curating a diverse genetic database.
read more11
02
2021
11/02/2021
Avellino Donates $25,000 to National Keratoconus Foundation to Support World Keratoconus Day and Disease Education
Menlo Park, California
Avellino Lab USA, Inc. (Avellino), in honor of World Keratoconus Day, today announced a $25,000 donation to the National Keratoconus Foundation (NKCF) to support their educational efforts for this sight-threatening disease. Keratoconus is a genetic eye disease that changes the cornea, distorting the front of the eye into a cone shape. It can affect both eyes, and without treatment, vision can progressively deteriorate.
read more08
03
2021
08/03/2021
Former World Economic Forum Member of the Managing Board Murat Sönmez Joins Avellino’s Board of Directors
Menlo Park, California
Avellino Lab USA, Inc. (Avellino) today announced the appointment of Murat Sönmez to the company’s Board of Directors. Murat is a former World Economic Forum Member of the Managing Board and founding head of their Centre for the Fourth Industrial Revolution, a public-private partnership institution he established in 2017 to help accelerate the benefits of science and technology among nations and organizations.
His depth of experience in digital technology, technology policy and global business will help guide Avellino as it continues to provide genetic-based diagnostics and eventual therapeutics and genetic data licensing to both the global medical and scientific community.
read more07
07
2021
07/07/2021
Avellino Partners with Sugentech, Inc. to Distribute SGTi-flex COVID-19 IgG Antibody Test
Menlo Park, California
Avellino and Sugentech, Inc., a bio- and nano- based technology and in-vitro diagnostic firm based in Korea, as part of their partnership agreement announced in August 2020, has begun distribution of Sugentech’s SGTi-flex COVID-19 IgG antibody test in the US. Sugentech received FDA Emergency Use Authorization (EUA) for the SGTi-flex COVID-19 IgG antibody test in April 2021.
read more06
28
2021
06/28/2021
Avellino Surpasses Two Million COVID-19 Tests in United States
Menlo Park, California
Avellino today announced that more than two million of its SARS-CoV-2/COVID-19 Tests (AvellinoCoV2) have now been performed in the United States.
Avellino was one of the first private companies in the U.S. to receive an Emergency Use Authorization (EUA) from the FDA for AvellinoCoV2 in March 2020. The test provided much-needed testing capacity during the initial surge of the pandemic in the U.S., in particular among populations in skilled nursing facilities, schools, colleges and government municipalities.
read more06
02
2021
06/02/2021
Avellino Launches AvaGenTM Nationwide as the First Genetic Test to Quantify Keratoconus Risk and Presence of Corneal Dystrophies
Menlo Park, California
Avellino today announced full nationwide availability in the U.S. of AvaGen™, The Genetic Eye Test, as the first genetic test that helps determine a patient’s risk of keratoconus and the presence of other corneal dystrophies. The test allows for more confident management and treatment for patients with these conditions in order to protect and preserve patient vision.
read more05
20
2021
05/20/2021
Laiq Ahmad Joins Avellino Labs as Chief Technology Officer
Menlo Park, California
Ahmad brings more than 22 years of experience to the role, with advanced knowledge of digital transformation, cloud technologies, big data, AI, and machine learning. In this role he will be leading technology, engineering and the innovation engine for the company’s next-generation sequencing applications and platforms, drive technology breakthroughs, and support Avellino Labs’ growth and innovation.
read more12
12
2020
12/12/2020
Avellino Expands its Board of Directors and Welcomes New Executive Management Members
Menlo Park, California
Avellino announced today the appointment of three new members to its Board of Directors.
read more11
09
2020
11/09/2020
Avellino Introduces New Multiplex Respiratory Panel
Menlo Park, California
Avellino announced today that the company has developed a novel multi-panel RT-PCR-based virus assay, AvellinoCoV2-Respiratory, which has been validated following the U.S. Food and Drug Adminiistration’s Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing CLIA guidelines.
read more08
25
2020
08/25/2020
Avellino and Sugentech Announce Strategic Collaboration
Menlo Park, California
Partnership Focused In Short Term On COVID-19 Genetic Diagnostics and Solutions, Long Term Collaboration On Partner Diagnostics and Therapeutics
read more08
13
2020
08/13/2020
Avellino Hits the 1-Million Genetic Test Milestone
Menlo Park, California
On track for over 10,000 gene-based diagnostic tests performed a day.
read more03
26
2020
03/26/2020
Bay Area Lab Aims to Distribute Millions of Coronavirus Test After Creating Their Own
NBC Bay Area
The NBC Bay Area Investigative Unit was granted exclusive access inside Avellino Laboratory, a Menlo Park-based genetic research firm that designed its own test for COVID-19. The lab plans to soon triple its staff in order to bolster its processing capacity to at least 7,000 coronavirus tests per day – potentially totaling millions of tests over the next year.
read more03
11
2020
03/11/2020
Avellino’s Coronavirus test now available, FDA approval pending
BioWorld
Avellino Lab USA Inc. has developed a diagnostic test for the novel coronavirus SARS-CoV-2, which has been validated in keeping with the U.S. Food and Drug Administration (FDA)’s Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency.
read more10
14
2019
10/14/2019
Avellino Labs Receives CLIA Certification For AvaGen
Menlo Park, California
Avellino Labs is proud to announce that it has received CLIA certification for AvaGen, a genetic diagnostic test for keratoconus and corneal dystrophies. With the certification, Avellino Labs can begin rolling out the availability of AvaGen nationwide.
read more05
23
2019
05/23/2019
Prominent Technologist William (Bill) F. Stasior Joins Avellino Labs Executive Advisory Committee
Menlo Park, California
Avellino Labs announced the addition of William F. Stasior to the company’s Executive Advisory Committee and consultant to the company. Mr Stasior will advance Avellino Labs genetic data management infrastructure to support the company’s growth and expanding application of its technology in health and precision medicine.
read more04
29
2019
04/29/2019
Avellino Labs Expands Medical Advisory Board With Internationally Renowned Ophthalmologists
Menlo Park, California
Avellino Labs, global biotechnology and genetic science innovators, announced that Eric Donnenfeld, MD; Edward Holland, MD; Richard Lindstrom, MD; and Elizabeth Yeu, MD have joined its board of medical advisors. These additions confirm Avellino Labs’ strong commitment to the future of diagnostics and therapeutic treatments for the cornea.
read more04
16
2019
04/16/2019
Eric Bernabei Joins Avellino Labs as Chief Sales and Marketing Officer
Menlo Park, California
Avellino Labs, global biotechnology and genetic science innovators, announced Eric Bernabei as the company’s chief sales and marketing officer (CSMO). The addition of Bernabei will further extend Avellino Labs’ leadership in global genetics and ophthalmic communities. Bernabei joins Avellino Labs with more than 20 years of product development and commercialization experience in ophthalmology.
read more